Global Custom Market Research Reports Provider Company

phone

Mitsubishi Tanabe Pharma Corp (4508) - Financial and Strategic SWOT Analysis Review

  • Published Date: 29 Aug 2018
  • Number of Pages: 57
  • Category: SWOT Analysis
  • Country: Japan
Mitsubishi Tanabe Pharma Corp (4508) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabes major brands include remicade, simponi, tenelia, ceredist, lexapro, flucort f, nanpao, alegysal bien and okinazole. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe and North America. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.

Mitsubishi Tanabe Pharma Corp Key Recent Developments

Jul 02,2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science - Toward the Innovative Drug Discovery for refractory Neurological Diseases
Jul 02,2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science
Jul 02,2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds
May 30,2018: Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
May 30,2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData

3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Mitsubishi Tanabe Pharma Corp - Key Facts 6
Mitsubishi Tanabe Pharma Corp - Key Employees 7
Mitsubishi Tanabe Pharma Corp - Key Employee Biographies 8
Mitsubishi Tanabe Pharma Corp - Major Products and Services 9
Mitsubishi Tanabe Pharma Corp - History 11
Mitsubishi Tanabe Pharma Corp - Company Statement 18
Mitsubishi Tanabe Pharma Corp - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Joint Venture 22
Section 2 Company Analysis 23
Company Overview 23
Mitsubishi Tanabe Pharma Corp - Business Description 24
Product Category: Ethical Drugs 24
Performance 24
Product Category: OTC Products 24
Performance 24
Product Category: Others 24
Performance 24
Product Category: Royalty Revenue 25
Performance 25
Geographical Segment: Asia 25
Performance 25
Geographical Segment: Europe 25
Performance 25
Geographical Segment: Japan 25
Performance 25
Geographical Segment: North America 25
Performance 25
Geographical Segment: Others 25
Performance 25
R&D Overview 25
Mitsubishi Tanabe Pharma Corp - Corporate Strategy 26
Mitsubishi Tanabe Pharma Corp - SWOT Analysis 27
SWOT Analysis - Overview 27
Mitsubishi Tanabe Pharma Corp - Strengths 27
Mitsubishi Tanabe Pharma Corp - Weaknesses 28
Mitsubishi Tanabe Pharma Corp - Opportunities 29
Mitsubishi Tanabe Pharma Corp - Threats 30
Mitsubishi Tanabe Pharma Corp - Key Competitors 31
Section 3 Company Financial Ratios 32
Financial Ratios - Capital Market Ratios 32
Financial Ratios - Annual Ratios 33
Performance Chart 36
Financial Performance 36
Financial Ratios - Interim Ratios 37
Financial Ratios - Ratio Charts 38
Section 4 Companys Lifesciences Financial Deals and Alliances 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40
Mitsubishi Tanabe Pharma Corp, Recent Deals Summary 41
Section 5 Companys Recent Developments 42
Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science - Toward the Innovative Drug Discovery for refractory Neurological Diseases 42
Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science 43
Jul 02, 2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds 44
May 30, 2018: Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development 45
May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development 46
Mar 26, 2018: Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development 47
Dec 13, 2017: Strategic Collaboration for the Development of the Antibody Drug to Treat Neurodegenerative Diseases including ALS 48
Nov 01, 2017: Mitsubishi Tanabe Pharma: Financial Results for the First Six Months of the Fiscal year ending March 31, 2018 49
Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct JOINUS, a New Drug Discovery Program Using Drug-Repositioning Compound Library 51
Sep 29, 2017: MT Pharma: Organizational Change and Personnel Change 52
Section 6 Appendix 53
Methodology 53
Ratio Definitions 53
About GlobalData 57
Contact Us 57
Disclaimer 57

List Of Tables


Mitsubishi Tanabe Pharma Corp, Key Facts 6
Mitsubishi Tanabe Pharma Corp, Key Employees 7
Mitsubishi Tanabe Pharma Corp, Key Employee Biographies 8
Mitsubishi Tanabe Pharma Corp, Major Products and Services 9
Mitsubishi Tanabe Pharma Corp, History 11
Mitsubishi Tanabe Pharma Corp, Other Locations 19
Mitsubishi Tanabe Pharma Corp, Subsidiaries 20
Mitsubishi Tanabe Pharma Corp, Joint Venture 22
Mitsubishi Tanabe Pharma Corp, Key Competitors 31
Mitsubishi Tanabe Pharma Corp, Ratios based on current share price 32
Mitsubishi Tanabe Pharma Corp, Annual Ratios 33
Mitsubishi Tanabe Pharma Corp, Annual Ratios (Cont...1) 34
Mitsubishi Tanabe Pharma Corp, Annual Ratios (Cont...2) 35
Mitsubishi Tanabe Pharma Corp, Interim Ratios 37
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 40
Mitsubishi Tanabe Pharma Corp, Recent Deals Summary 41
Currency Codes 53
Capital Market Ratios 53
Equity Ratios 54
Profitability Ratios 54
Cost Ratios 55
Liquidity Ratios 55
Leverage Ratios 56
Efficiency Ratios 56

List Of Figures


Mitsubishi Tanabe Pharma Corp, Performance Chart (2014 - 2018) 36
Mitsubishi Tanabe Pharma Corp, Ratio Charts 38
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 39
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 40

Royal Mail plc (RMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

View Report

Leclanche SA (LECN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

View Report

NEC Corp (6701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports